BiTE: Teaching antibodies to engage T-cells for cancer therapy.
about
Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cellsThe role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemiaTranslating basic mechanisms of IgG effector activity into next generation cancer therapiesAre BiTEs the "missing link" in cancer therapy?Mechanisms of action of therapeutic antibodies for cancerIdentification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activityModern Technologies for Creating Synthetic Antibodies for Clinical application.Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling.Immunological treatment options for locoregionally advanced head and neck squamous cell carcinomaT cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cellApplication of quantitative pharmacology in development of therapeutic monoclonal antibodiesInterleukin-15:Interleukin-15 receptor α scaffold for creation of multivalent targeted immune moleculesCancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody.Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cellsLarge-Scale Purification of r28M: A Bispecific scFv Antibody Targeting Human Melanoma Produced in Transgenic Cattle.Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive MalignanciesTargeting T cells with bispecific antibodies for cancer therapyBlinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE(®) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications.Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs.Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells.Emerging therapies for acute myeloid leukemia: translating biology into the clinic.ImmTACs: Novel bi-specific agents for targeted cancer therapy.CD28 and 41BB Costimulation Enhances the Effector Function of CD19-Specific Engager T Cells.Bispecific antibodies: design, therapy, perspectives.Development of a novel affinity chromatography resin for platform purification of bispecific antibodies with modified protein a binding avidity.Bispecific antibodies in cancer immunotherapy.
P2860
Q21136080-FDBC150A-A5C1-45EC-AD76-FC72DCC95F6BQ26744280-1CC6DB48-16D0-42B1-806E-91E2E7428B6DQ26991899-508AA4D3-81F5-40AC-A6E9-4EC1C3279AE9Q28083907-5CC181BF-4A60-431E-A262-AA85758E10F5Q28385366-EF7CE144-1AA6-4097-A581-4BC6ACB1628CQ28487387-A062AFB6-9FF2-4389-B84B-17157EC5AA2FQ30467308-2D4D726D-33FF-4DCB-884B-161FCB4E442FQ33966937-5237291C-4B9E-4DCF-9D02-0019BC880A4FQ34181954-364BD8F4-4B8D-4FAC-84ED-F82E66DA6915Q34227769-FB84F605-857F-4EA6-AC84-82BACE309EBFQ34293689-C5C58285-64E6-4E17-9A8C-8FF40B5FD457Q34626998-AC890297-A830-46B1-B167-A1DE082CCDB7Q34983200-57260106-6298-4041-AB20-F024B412E0DCQ35005791-297E1B13-840C-4832-90AD-A3C49CE46F83Q35368001-3B22AE69-9810-4FA5-9CE6-ED344E93BD59Q35808466-C6BA7289-3A8C-4D32-9226-B0578DC1BEF2Q35824663-AF960964-40B5-4BBD-A985-24EAF624EE5EQ36965071-65A279EE-D5E9-49DB-8A0D-724EDFFBFFA6Q37220742-4282E168-08A5-4F92-B2C6-07487872FEFBQ38205447-9B2E7598-B0ED-4018-B311-51AD16D33BB5Q38364462-D96FBE00-1C99-43FE-8E6C-7378D48D1757Q40996964-29C37C8B-5122-4EA5-8EE4-FCE20D1679D0Q41984963-76464C8C-55A8-4AF3-81E4-5CE5D37546E2Q43225889-0D189884-E7C3-4689-AAC2-E82141B496FDQ45870963-DD63FCB2-E494-4336-A286-E11987357C81Q49195146-01729A56-AFF9-41AE-8567-6CEBF7D90411Q49718154-77C285CF-CC46-4B21-925C-7085AE19BA52Q51309023-3FC81F4F-A6B7-4237-9EEF-0164392373DE
P2860
BiTE: Teaching antibodies to engage T-cells for cancer therapy.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
BiTE: Teaching antibodies to engage T-cells for cancer therapy.
@ast
BiTE: Teaching antibodies to engage T-cells for cancer therapy.
@en
BiTE: Teaching antibodies to engage T-cells for cancer therapy.
@nl
type
label
BiTE: Teaching antibodies to engage T-cells for cancer therapy.
@ast
BiTE: Teaching antibodies to engage T-cells for cancer therapy.
@en
BiTE: Teaching antibodies to engage T-cells for cancer therapy.
@nl
prefLabel
BiTE: Teaching antibodies to engage T-cells for cancer therapy.
@ast
BiTE: Teaching antibodies to engage T-cells for cancer therapy.
@en
BiTE: Teaching antibodies to engage T-cells for cancer therapy.
@nl
P2093
P1476
BiTE: Teaching antibodies to engage T-cells for cancer therapy.
@en
P2093
Patrick A Baeuerle
Peter Kufer
Ralf Bargou
P577
2009-02-01T00:00:00Z